TrialDiabetes, obesity & metabolism2011

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

P Barrington et al.PubMed ↗Publisher ↗

No numbers read from the abstract.